Literature DB >> 12694568

FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.

N M van Sorge1, W-L van der Pol, J G J van de Winkel.   

Abstract

Leukocyte Fcgamma receptors (FcgammaR) confer potent cellular effector functions to the specificity of IgG. FcgammaR-induced leukocyte functions, including antibody-dependent cellular cytotoxicity, phagocytosis, superoxide generation, degranulation, cytokine production and regulation of antibody production, are essential for host defense and immune regulation. The efficacy of IgG-induced FcgammaR function displays inter-individual heterogeneity due to genetic polymorphisms of three FcgammaR subclasses, FcgammaRIIa (CD32a), FcgammaRIIIa (CD16a), and FcgammaRIIIb (CD16b). FcgammaR polymorphisms have been associated with infectious and autoimmune disease, or with disease severity. FcgammaR polymorphisms may furthermore serve as markers for therapeutic efficacy and side-effects of treatment with monoclonal antibodies. In this review, FcgammaR function and the relevance of FcgammaR polymorphisms as prognostic markers for inflammatory disease and antibody-based immunotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12694568     DOI: 10.1034/j.1399-0039.2003.00037.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  79 in total

Review 1.  Engineered CD3 antibodies for immunosuppression.

Authors:  L Renders; T Valerius
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 2.  Fcepsilon- and Fcgamma-receptor signaling in diseases.

Authors:  Zen-Ichiro Honda
Journal:  Springer Semin Immunopathol       Date:  2006-11-15

3.  Extravasations and emigration of neutrophils to the inflammatory site depend on the interaction of immune-complex with Fcgamma receptors and can be effectively blocked by decoy Fcgamma receptors.

Authors:  Rangaiah Shashidharamurthy; Randolph A Hennigar; Sebastien Fuchs; Purani Palaniswami; Melanie Sherman; Periasamy Selvaraj
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

Review 4.  Mechanisms and regulation of the gene-expression response to sepsis.

Authors:  Timothy T Cornell; James Wynn; Thomas P Shanley; Derek S Wheeler; Hector R Wong
Journal:  Pediatrics       Date:  2010-05-17       Impact factor: 7.124

5.  Bone marrow aspirate and biopsy: a pathologist's perspective. II. interpretation of the bone marrow aspirate and biopsy.

Authors:  Roger S Riley; David Williams; Micaela Ross; Shawn Zhao; Alden Chesney; Bradly D Clark; Jonathan M Ben-Ezra
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 6.  The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases.

Authors:  Alina Sesarman; Gestur Vidarsson; Cassian Sitaru
Journal:  Cell Mol Life Sci       Date:  2010-03-09       Impact factor: 9.261

7.  The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.

Authors:  Manfred Ahlgrimm; Michael Pfreundschuh; Markus Kreuz; Evi Regitz; Klaus-Dieter Preuss; Joerg Bittenbring
Journal:  Blood       Date:  2011-09-07       Impact factor: 22.113

8.  IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Authors:  Carol T Cady; Maree S Powell; Ronald J Harbeck; Patricia C Giclas; James R Murphy; Rohit K Katial; Richard W Weber; P Mark Hogarth; Syd Johnson; Ezio Bonvini; Scott Koenig; John C Cambier
Journal:  Immunol Lett       Date:  2009-12-30       Impact factor: 3.685

9.  Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A.

Authors:  Rangaiah Shashidharamurthy; Fang Zhang; Aaron Amano; Aparna Kamat; Ravichandran Panchanathan; Daniel Ezekwudo; Cheng Zhu; Periasamy Selvaraj
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

10.  Fc Gamma Receptor IIA (CD32A) R131 Polymorphism as a Marker of Genetic Susceptibility to Sepsis.

Authors:  Jaqueline Beppler; Patrícia Koehler-Santos; Gabriela Pasqualim; Ursula Matte; Clarice Sampaio Alho; Fernando Suparregui Dias; Thayne Woycinck Kowalski; Irineu Tadeu Velasco; Renato C Monteiro; Fabiano Pinheiro da Silva
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.